Sprint Bioscience AB (publ) (5JA1.F)
- Previous Close
0.0410 - Open
0.0506 - Bid 0.0556 x --
- Ask 0.0806 x --
- Day's Range
0.0506 - 0.0506 - 52 Week Range
0.0378 - 0.1678 - Volume
6,219 - Avg. Volume
101 - Market Cap (intraday)
5.696M - Beta (5Y Monthly) -0.07
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date May 7, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden.
www.sprintbioscience.comRecent News: 5JA1.F
View MorePerformance Overview: 5JA1.F
Trailing total returns as of 4/24/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 5JA1.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 5JA1.F
View MoreValuation Measures
Market Cap
4.62M
Enterprise Value
2.33M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.49
Price/Book (mrq)
3.45
Enterprise Value/Revenue
0.39
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-27.63%
Return on Assets (ttm)
-22.46%
Return on Equity (ttm)
-98.67%
Revenue (ttm)
66.14M
Net Income Avi to Common (ttm)
-18.28M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
25.06M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-18.16M